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Introduction
Pulmonary embolism (PE) leads to the hospitalization or death of over 30 000 Canadians, 225 000 Americans and 300 000 Europeans each year [1, 2] and its rate of hospitalization has increased substantially over the past two decades [3] [4] [5] . Most research on prognosis after PE has focused on outcomes such as mortality and PE recurrence, whereas patient-centered outcomes such as healthrelated quality of life (HRQOL) have been less well studied. Although early diagnosis and treatment of PE results in the vast majority of patients surviving the acute episode, and stable PE patients are increasingly being safely treated in the outpatient setting [6, 7] , our group and others have recently shown that functional limitation and reduced quality of life (QOL) occur frequently within a year of PE diagnosis [8] [9] [10] [11] [12] .
The PEmbQoL questionnaire, a PE-specific QOL measure, was recently developed and validated and has been used to quantify disease-specific QOL in RCT, cohort and cross-sectional studies of patients with PE [9, 11, 13, 14] . However, to date, the absence of a known minimal clinically important difference (MCID) for the PEmbQoL has limited the interpretation of scores and changes in scores of this measure for patients, physician and researchers. For example, in our recent study that evaluated dyspnea and quality of life during 1 year after PE [8] , although we were able to describe changes in PEmbQoL scores over time, we were unable to comment on the clinical relevance of these changes.
In order to assess the clinical effectiveness of treatments, the amount of improvement that is clinically important to patients must be defined [15] . The smallest change in the amount of a measure that is significant or meaningful to patients is considered the MCID [15, 16] . There are three methods to determine the MCID of a measure: (i) anchor-based approaches, which compare the amount of change in a measure with the amount of change in an external validated measure(s) that is considered to be an anchor [17] ; (ii) distribution-based approaches, which rely on the 'statistical characteristics' of the outcome [17] ; and (iii) the Delphi approach, which is an opinion-based method to calculate MCID by convening an expert panel to obtain consensus [15] .
We used data from the ELOPE Study, a prospective, observational, multicenter cohort study of long-term outcomes after a first episode of acute PE [9] , to conduct an analysis to determine an MCID for PEmbQoL and its subscales using anchor-based and distribution-based statistical approaches. We also aimed to assess, based on the identified MCID, the proportions of patients whose PEspecific QoL improved over study follow-up.
The PEmb-QoL questionnaire is provided in Data S1.
Materials and methods

Study population
Patients with acute PE were recruited from the emergency departments, outpatient clinics and inpatient wards of five university-affiliated hospitals in Quebec, Ontario and Nova Scotia, Canada, from June 2010 to February 2013. Patients were potentially eligible to participate in the study if they were 18 years or older, had a first episode of acute PE that was objectively diagnosed within the last 10 days, and were treated with anticoagulants ( Fig. 1 ).
Exclusion criteria included contraindications to or inability to perform a cardiopulmonary exercise test or a 6-min walking distance test, contraindications to CT pulmonary angiography, severe comorbidity, previous deep vein thrombosis, life expectancy of under 1 year, pregnant or lactating, unable to read a questionnaire in English or French, unable to attend study follow-up visits, or unable or unwilling to provide written informed consent. A detailed list of study inclusion and exclusion criteria has been published [9] .
Ethics approval was obtained from the relevant committees at each hospital center, and written informed consent was obtained from all patients prior to study entry.
Study procedures relevant to this sub-study
Baseline and follow-up assessments. At study entry, demographic and clinical characteristics were recorded using a standardized case report form. Participants were asked to complete generic QOL (Short-Form [SF]-36 [18, 19] ), PE-specific QOL (PEmbQoL [11] ) and dyspnea (University of California at San Diego Shortness of Breath Questionnaire [SOBQ] [20] ) questionnaires. Follow-up visits were scheduled at 1, 3, 6 and 12 months. At each visit, patients completed the above-noted QOL and dyspnea questionnaires.
Study outcomes.
We assessed PE-specific QOL at the above-noted time-points using the validated PEmb-QoL questionnaire, a 40-item PE-specific QOL questionnaire that yields scores in six domains. The six domains are: frequency of complaints, limitations to activities of daily living (ADL), social limitations, intensity of complaints, emotional complaints and work-related problems. Total scores for each domain range from 0 to 100; lower scores indicate better QOL [11, 21] . To estimate a total PEmbQoL score, the average of the scores of all six domains was calculated.
Study anchors. We chose generic QOL and dyspnea severity as anchors to estimate the MCID for PEmbQoL. We assessed generic QOL using the validated SF-36 questionnaire, which measures eight domains (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health) and produces two summary scores: physical and mental component summary scores (PCS and MCS, respectively). Higher scores indicate better QOL. Published norms for SF-36 scores are available for numerous diseases, including cardiovascular diseases such as congestive heart failure, angina and chronic lung disease but not PE, to our knowledge [22] . We assessed dyspnea severity with the validated SOBQ, a 24-item questionnaire on shortness of breath with activities of daily living [20] . Total scores range from 0 to 120, with lower scores indicating less shortness of breath.
Statistical analysis
We summarized demographic and clinical characteristics of study subjects as means and standard deviations (SD) and medians, or proportions, as appropriate. Baseline QOL and dyspnea scores were compared by categories of sex, age and body mass index (BMI) using the t-test and analysis of variance (ANOVA) as appropriate.
Within-patient changes in PEmbQoL, PCS, MCS and SOBQ scores from the first assessment to each subsequent assessment were calculated. Based on the published literature, at least a 4-point change in PCS and MCS scores [18, 23] and a 5-point change in SOBQ score [24] were considered to represent 1-unit of MCID in these measures.
We used time-varying repeated-measures mixed-effect models to estimate the anchor-based MCID for PEmbQoL using PCS, MCS and SOBQ as anchors. The random effect of intercept was included in the model for each outcome. In all models, time was included as a continuous variable, and each anchor was included as a timevarying independent dichotomous variable (coded as patient experienced change of at least one unit MCID vs. less than one unit). Distribution-based MCIDs were calculated using effect sizes of changes from baseline to each Participants (n = 82) 1 month follow-up (n = 80)
Inclusion criteria (n = 984) Patients with a first episode of acute PE that was objectively diagnosed within the last 10 days, seen in the emergency departments, outpatient clinics and in-patient wards of five participating hospitals, who were 18 years or older and were planned to be treated with anticoagulants subsequent time-point. The estimations were based on considering 0.5 and 0.8 to represent medium and large effect sizes, based on Cohen's definition [25] , respectively, for PEmbQoL total scores and its six domains. Calculation of MCID based on both medium and large effect sizes provides additional information on the interpretation of PEmbQoL results to readers. In sensitivity analyses, to assess the stability of parameter estimation, MCIDs adjusted for age, sex and BMI were calculated. In addition, multiple imputation using the chained equations method was carried out to impute missing data [26] . Evaluation of missing data suggested that missingness was at random. In order to be reasonably certain about the statistical reproducibility of the results, Monte Carlo error estimates of coefficients, standard errors and P-values were evaluated.
Finally, based on the MCID determined by our analyses, we calculated the proportions of patients who improved from the first assessment to each subsequent assessment, using within-patient changes in PEmbQoL scores. We performed all statistical analyses using Stata Statistical Software: version 14 IC (StataCorp LP, College Station, TX, USA). A two-sided P value of 0.05 was considered statistically significant.
Results
Patient characteristics
Among 984 patients screened, 150 were eligible and 100 consented to be enrolled in the ELOPE study. As the PEmbQOL questionnaire became available to be included as a study outcome measure in 2010, after recruitment had already started, 82 ELOPE patients were able to be included in this sub-study to estimate PEmbQOL MCID. Their mean age was 49.4 years, 60% were male and 84% had their PE diagnosed and managed in the outpatient setting. PE was unprovoked in 77%, and 33% of patients had concomitant deep vein thrombosis. The median number of days from diagnosis to study enrollment was 7 days, and most patients were treated with 5-7 days of low-molecular-weight heparin (LMWH) followed by warfarin (Table 1) .
Baseline QOL and dyspnea scores
Baseline QOL and dyspnea scores for the 82 patients are presented in Table 2 . Women had worse QOL and dyspnea scores at baseline than men. Older patients had better QOL and dyspnea scores than younger patients.
Anchor-based MCID for PEmbQoL and its subscales
Minimal clinically important differences for PEmbQOL and its six domains using PCS, MCS and SOBQ as anchors are shown in Table 3 . For PEmbQoL-total, the estimated MCID based on PCS was À14.0 (95% CI: À17.9, À10.0) points; the estimated MCIDs for PEmbQoL-total based on MCS and SOBQ were lower (À10.1 points) and higher (À17.5 points) than PCS, respectively.
Sensitivity analysis
The coefficients (MCIDs) of models adjusted for age, sex and BMI were similar to unadjusted coefficients (Table S1 ). Similarly, results were consistent for estimation of MCIDs after multiple imputation for both unadjusted and adjusted models (Tables S2 and S3) .
Distribution-based MCID for PEmbQoL and its domains
Distribution-based MCIDs for PEmbQoL-total and its six domains based on changes from baseline to each assessment time-point are presented in Table 4 . An acceptable range (based on a medium to large effect) for distribution-based MCID for PEmbQoL-total, for the period of baseline to 6 months, was 12.4-19.8. Among the domains, PE-Work had the widest ranges and highest values and PE-Emotional complaints had the narrowest ranges and lowest values for their MCIDs.
The average of calculated MCIDs based on anchors (PCS, MCS and SOBQ) is~14 points, and considering MCIDs based on both anchor-and distribution-based results, the average is 14.8. Therefore, we rounded this and introduced a 15-point change as the MCID for the PEmb-QoL questionnaire. Based on a 15-point change in PEmbQOL-total as the MCID, 42%, 59%, 66% and 75% of patients experienced at least one MCID unit of improvement in PEmbQoL from baseline to 1, 3, 6 and 12 months, respectively.
Discussion
The present study was conducted to estimate the MCID for PEmbQoL, a PE-specific QOL measure that is being increasingly used in studies of outcome after PE. Two methods were used: an anchor-based approach, with three different anchors (PCS, MCS, and SOBQ), and a Our study has a number of strengths. The source population was well defined, and we excluded patients with prior PE or deep vein thrombosis. We assessed a range of relevant functional outcomes prospectively, at multiple time-points, using validated measures and questionnaires, ADL, activities of daily living. *MCIDs were calculated based on a medium effect (effect size = 0.5) and a large effect (effect size = 0.8). in a multicenter study. To comprehensively estimate the anchor-based MCIDs for the PEmb-QOL questionnaire and its domains [11] , we used both physical and mental components of QOL [27, 28] and dyspnea severity [20] measures as anchors. We used both anchor-and distribution-based [29] methods to estimate the MCIDs. There are also several limitations to our study. Our sample size was modest. We had no information on QOL and presence or severity of dyspnea before the diagnosis of PE. Because the primary aim of the study was to assess exercise limitation after PE using cardiopulmonary exercise testing [9] , patients had to be free of significant comorbidity to participate in the study, and the majority of our patients with PE were diagnosed and treated in the outpatient setting; hence we cannot be certain that the MCID would apply to a broad spectrum of patients (i.e. sicker, hospitalized patients) with PE. Each method of MCID calculation has its own limitations. Anchor-based methods of identifying an MCID can be limited by selection of the anchor, which is a subjective assessment, recall bias, importance of cut-offs of anchors, statistical approaches and sample characteristics [15, 30] . Limitations of distribution-based methods include that they are based on purely statistical characteristics, with a lack of valuation of the clinical relevance of a given difference [15, 30] . Delphi methods, which use experts' opinions to define an MCID, may be limited by failure of experts to define what is important to patients. Therefore, we decided to calculate the MCID by using anchor-and distributionbased methods.
In our study, we attempted to minimize potential factors that can influence the validity of the anchor-based method; for example, patients completed the PEmb-QoL and anchor questionnaires at the same time, thus reducing recall bias, the selected cut-offs for PCS, MCS and SOBQ were based on their validated MCIDs [22, 24] , and our use of time-varying repeated-measures mixed-effect models, by linking the changes in each anchor to the changes in PEmb-QoL over study follow-up, helps to provide the most precise MCID. Although distribution-based methods can be used to calculate an MCID, as noted above these methods are purely statistically based and the obtained MCID is not linked to what matters to patients. Thus, MCIDs derived from distribution-based methods are not recommended as the sole method to identify MCID [30] . However, using anchor-based methods, MCIDs are directly linked to what is meaningful change to patients by using an external valid measure as the anchor.
To our knowledge, this is the first study to estimate the MCID for PEmbQOL, despite the fact that the questionnaire has already been validated in five language versions: Dutch [11] , English [11] , French [31] , German [32] and Norwegian [33] .
The estimated MCIDs for PEmbQoL based on MCS and SOBQ were lower and higher, respectively, than MCIDs based on PCS. The nature of changes in PCS, MCS and SOBQ scores over study follow-up might explain these differences. As reported previously [8] , MCS scores in the ELOPE population showed a smaller degree of improvement over time compared with PCS scores, especially from baseline to 1 month. Therefore, a smaller change in MCS reflects a larger change in PEmbQOL, in comparison with PCS. Conversely, SOBQ scores over time had a greater degree of improvement, similar to the pattern noted for PCS. Therefore, a greater change in SOBQ reflects a smaller change in PCS. We consider PCS and SOBQ to be more appropriate anchors than MCS to estimate MCID for PEmbQoL, as PE is primarily a physical condition.
Estimates of the MCIDs for total PEmbQoL and PEmbQoL domains changed very little (< 3%) after adjustment for age, sex and BMI, as did the estimated MCIDs after multiple imputation for missing data. These results confirm the robustness of the estimated MCIDs.
The calculated ranges for MCIDs for PEmbQoL-total and for each domain based on effect sizes differed somewhat depending on the period analyzed (e.g. baseline to 6 months vs. baseline to 3 months). The differences in width of ranges for MCID among PEmbQoL domains can probably be explained by the structure of the questionnaire items and their responses (e.g. Likert scale from 1 to 6 for questions in the emotional complaints subscale vs. 1/2 [i.e. Yes/No] for questions in the work-related problems domains). Despite these differences, all the calculated ranges in MCID for PEmbQoL-total for the four time periods analyzed overlapped, with a range of overlap from 12.4 to 17.1. Finally, it is worth noting that the calculated MCIDs for the Social limitations and Intensity of complaints domains cannot be used to interpret individuals' changes over time, as these domains have only one and two questions in the PEmbQoL questionnaire, respectively.
Identifying the MCID for the PEmbQOL questionnaire will help with the assessment of the clinical effectiveness of treatments for PE and enable clinicians and researchers to interpret the amount of change of PE-related QOL, based on what matters to patients. In conclusion, we found that a 15-point change in PEmbQol-total score appears to be a reasonable MCID for this PE-specific QOL questionnaire. We previously reported that on average, QOL and dyspnea scores improved during the year after a first episode of PE [8] . We further characterize that change here by showing that the proportion of patients with at least one MCID unit of improvement in PEmbQoL increased over time, to 75% at 12 months after PE.
This new, practical and important information on the MCID of PEmbQoL can be used by researchers and clinicians to measure and interpret changes in PE-specific QOL over time, or as an outcome measure in clinical trials of interventions to treat PE. 
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Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article: Table S1 . Minimal clinically important difference (MCID) and its 95% CI for PEmbQoL and its six domains using the anchor-based approach in time-varying repeated-measures mixed-effect models, adjusted for age, sex and body mass index (BMI). Table S2 . Minimal clinically important difference (MCID) and its 95% CI for PEmbQoL total using the anchorbased approach in time-varying repeated-measures mixedeffect models after multiple imputations for missing data. Table S3 . Minimal clinically important difference (MCID) and its 95% CI for PEmbQoL total using the anchorbased approach in time-varying repeated-measures mixedeffect models after multiple imputations for missing data, adjusted for age, sex and body mass index (BMI). Data S1. PEmb-QoL questionnaire (reproduced from [1] ).
